50528-73-9

Basic information

• Product Name: 4-BENZYLOXYPHENYL ISOCYANATE
• Synonyms: 4-BENZYLOXYPHENYL ISOCYANATE;4-Benyloxyphenylisocyanate;4-BENZYLOXYPHENYL ISOCYANATE 98%;4-Benzyloxyphenyl isocyanate,97%;1-(Benzyloxy)-4-isocyanatobenzene;1-(Benzyloxy)-4-isocyanatobenzene, Benzyl 4-isocyanatophenyl ether;1-isocyanato-4-phenylmethoxybenzene
• CAS NO: 50528-73-9
• Molecular Formula: C₁₄H₁₁NO₂
• Molecular Weight: 225.24
• Product Categories: Isocyanates;Nitrogen Compounds;Organic Building Blocks
• Mol File: 50528-73-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 60-62 °C(lit.)
• Boiling Point: 129 °C0.2 mm Hg(lit.)
• Flash Point: 158.5 °C
• Appearance: light yellow to slightly brown crystalline mass
• Density: 1.1508 (rough estimate)
• Vapor Pressure: 4.37E-05mmHg at 25°C
• Refractive Index: 1.5780 (estimate)
• Storage Temp.: 0-6°C
• CAS DataBase Reference: 4-BENZYLOXYPHENYL ISOCYANATE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYLOXYPHENYL ISOCYANATE(50528-73-9)
• EPA Substance Registry System: 4-BENZYLOXYPHENYL ISOCYANATE(50528-73-9)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 2206
• WGK Germany: 3
• Hazardous Substances Data: 50528-73-9(Hazardous Substances Data)

Usage

Chemical Properties

LIGHT YELLOW TO SLIGHTLY BROWN CRYSTALLINE MASS

InChI:InChI=1/C14H11NO2/c16-11-15-13-6-8-14(9-7-13)17-10-12-4-2-1-3-5-12/h1-9H,10H2

Upstream product

• 75-44-5 phosgene 
• 51388-20-6 4-benzyloxyaniline hydrochloride 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 6373-46-2 p-benzyloxyaniline 
• 100-02-7 4-nitro-phenol 
• 100-44-7 benzyl chloride 
• 1145-76-2 benzyl 4-nitrophenyl ether 

Downstream Products

• 110080-44-9 (4-benzyloxy-phenyl)-carbamic acid-(2-diethylamino-ethyl ester) 
• 220697-91-6 (-)-(3aS)-1-benzyl-3a,8-dimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl-N-4'-benzyloxyphenylcarbamate 
• 220697-90-5 (-)-(3aS)-eseroline-4'-benzyloxyphenylcarbamate 
• 872599-15-0 1-(4-benzyloxy-phenyl)-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-urea 
• 17273-08-4 1-{4-[bis-(2-chloroethyl)-amino]-phenyl}-3-(4-hydroxyphenyl) urea 
• 617245-64-4 4-[3-(4-benzyloxy-phenyl)-1-methyl-ureido]-N-(1-benzyl-piperidin-4-yl)-2-methoxy-benzamide 
• 459451-66-2 6-(2-Diethylamino-ethyl)-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid (4-benzyloxy-phenyl)-amide 
• 436152-89-5 8-((((4-(benzyloxy)phenyl)amino)carbonyl)amino)-N-methyl-2-oxooctanamide 
• 1038917-13-3 (S)-{5-[3-(4-benzyloxy-phenyl)-ureido]-5-p-tolylcarbamoyl-pentyl}-carbamic acid tert-butyl ester 
• 1059702-81-6 (R)-3-(3-(4-(benzyloxy)phenyl)ureido)-4-(trimethylammonio)butanoate acetate 
• 229643-02-1 4-(5-hydroxytetrazol-1-yl)-1-benzyloxybenzene 
• 895638-48-9 C₁₄H₁₄N₂O₃ 
• 1119859-74-3 3-amino-N-[4-(benzyloxy)phenyl]-1H-indazole-1-carboxamide 
• 945865-02-1 N-{3-[1-ethyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]phenyl}-N'-{4-[(phenylmethyl)oxy]phenyl}urea 

Relevant articles and documents

2-[3-(4-morpholinyl)propylamine]-3-aryl-4-quinolinone compounds and application thereof

The invention belongs to the technical field of medicines and relates to 2-[3-(4-morpholinyl)propylamine]-3-aryl-4-quinolinone compounds and an application thereof. 2-[3-(4-morpholinyl)propylamine]-3-aryl-4-quinolinone derivatives comprise stereisomers and pharmaceutically applicable salts of the compounds and have the general structural formula shown in the description, wherein R is described inthe claims and description. The 2-[3-(4-morpholinyl)propylamine]-3-aryl-4-quinolinone derivatives and pharmaceutically applicable acid-added salts of the compounds can be combined with existing medicines or used separately to serve as influenza virus inhibitors to treat influenza and have better curative effects on various type-A influenza in particular.

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: Structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain

1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl) piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52) showed a 7-fold increase in potency, a 65-fold increase in Cmax, and a 3300-fold increase in AUC over its adamantane analogue 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl) urea (2). This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mechanical withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.

4'-Hydroxyphenylcarbamates of (3aS)eseroline and (3aS)-N(1)- noreseroline: Potential metabolites of the Alzheimer's anticholinesterase drug phenserine

4'-Hydroxyphenylcarbamates of (3aS)-eseroline (3) and (3aS)-N(1)- noreseroline (4), as predicted metabolites of phenserine (1), were synthesized. Biological evaluation showed that 3 and 4 possessed potent activities for inhibition of acetylcholinesterase and butyrylcholinesterase in vitro. In contrast the intermediates, 4'-benzyloxyphenserine (8) and 4'- benzyloxy N(1)-benzylphenserine (12), demonstrated unusually potent and selective activities against butyrylcholinesterase.